Possible symptoms of hemorrhagic syndrome. Treatment . Minor bleeding rarely require special treatment, a significant (at the risk of thrombosis) – may require the assignment of protamine sulfate (protamine sulfate leads to a partial reduction in boldenone activity bemiparin sodium 2 hours after intravenous administration at a dose of 1.4 mg / 100 IU ).
Interaction with other drugs
bemiparin sodium should not be mixed in the same container with other drugs for parenteral administration.
Do not co-administration of sodium bemiparin is recommended with vitamin K antagonists and other anticoagulants, acetyl salicylic acid and other salicylates ticlopidine, clopidogrel and other aggregation inhibitors platelets, and systemic glucocorticosteroids dextran due to potentiation of the pharmacological action of bemiparin sodium and increased risk of bleeding. In the case of inevitability appropriate combination therapy should be used under close clinical and laboratory control sodium bemiparin.
Concomitant use of drugs that increase the concentration of boldenone potassium in serum, also need to be carried out only under careful medical supervision.
The use of sodium bemiparin, as well as other drugs heparin, together with nitroglycerin intravenous reduces the efficiency of the anticoagulant.
Bemiparin sodium can not be administered intramuscularly.
In order to avoid the risk of hematoma during therapy not be used by the intramuscular route of administration other drugs.
Various low molecular weight heparins do not always have equivalent activity, so for each drug in this class is necessary to observe specific dosage regimen and the method of application.
bemiparin sodium, as well as other low molecular weight heparins can suppress adrenal secretion of aldosterone, which may cause hyperkalemia, especially in patients with diabetes mellitus, chronic renal insufficiency prior metabolic acidosis, increased concentration of potassium in plasma or in patients taking potassium-sparing drugs. The risk of hyperkalemia is increased in proportion to the duration of therapy, but such hyperkalemia is usually reversible. In high-risk patients before starting therapy with boldenone is necessary to determine plasma electrolytes and regular monitoring of the relevant indicators in the course of treatment, especially if the duration of therapy with more than seven days.
In rare cases at the beginning of heparin therapy, observed a light transient thrombocytopenia type I (number of platelet – 100000-150000 / mm 3 ), associated with temporary platelet activation (see.
As a rule, such a condition does not cause complications and does not require discontinuation of therapy with boldenone
In the rare cases when heparin therapy is observed the development of severe immune thrombocytopenia type II with platelet counts significantly below.